The HDAC Inhibitors Scriptaid and LBH589 Combined with the Oncolytic Virus Delta24-RGD Exert Enhanced Anti-Tumor Efficacy in Patient-Derived Glioblastoma Cells.

The HDAC Inhibitors Scriptaid and LBH589 Combined with the Oncolytic Virus Delta24-RGD Exert Enhanced Anti-Tumor Efficacy in Patient-Derived Glioblastoma Cells.

A phase I/II trial for glioblastoma with the oncolytic adenovirus Delta24-RGD was recently completed. Delta24-RGD conditionally replicates in cells with a disrupted retinoblastoma-pathway and enters cells via αvβ3/5 integrins. Glioblastomas are differentially sensitive to Delta24-RGD. HDAC inhibitor...

Full description

Bibliographic Details
Main Authors: Lotte M E Berghauser Pont, Anne Kleijn, Jenneke J Kloezeman, Wouter van den Bossche, Johanna K Kaufmann, Jeroen de Vrij, Sieger Leenstra, Clemens M F Dirven, Martine L M Lamfers
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4436250?pdf=render

Internet

http://europepmc.org/articles/PMC4436250?pdf=render

Similar Items